Jason Karlawish of the Perelman School of Medicine says that the new data on experimental Alzheimer’s drug lecanemab show reason for both optimism and caution.
https://nyti.ms/3XJZ4Ss The New York TimesJason Karlawish of the Perelman School of Medicine says that the new data on experimental Alzheimer’s drug lecanemab show reason for both optimism and caution.
https://nyti.ms/3XJZ4Ss The New York Times